$RSLS
ReShape Lifesciences Inc. Stock $rsls

$rsls Overview Financials Valuation SEC Filings Company Website

2018 Q2 Form 10-Q Financial Statement

#000142757018000031 Filed on May 10, 2018

Income Statement

Concept	2018 Q2	2018 Q1	2017 Q1
Revenue	$2.732M	$1.346M	$1.472M
YoY Change	39.17%	-8.56%	37.7%
Cost Of Revenue	$1.732M	$769.0K	$823.0K
YoY Change	74.95%	-6.56%	32.32%
Gross Profit	$1.000M	$577.0K	$649.0K
YoY Change	2.77%	-11.09%	45.19%
Gross Profit Margin	36.6%	42.87%	44.09%
Selling, General & Admin	$7.250M	$10.01M	$5.940M
YoY Change	23.87%	68.45%	330.75%
% of Gross Profit	725.0%	1734.14%	915.25%
Research & Development	$3.352M	$2.639M	$2.400M
YoY Change	21.45%	9.96%	-4.46%
% of Gross Profit	335.2%	457.37%	369.8%
Depreciation & Amortization	$1.390M	$100.0K	$30.00K
YoY Change	3375.0%	233.33%	-25.0%
% of Gross Profit	139.0%	17.33%	4.62%
Operating Expenses	$10.60M	$12.65M	$8.340M
YoY Change	23.09%	51.62%	114.34%
Operating Profit	-$9.602M	-$12.07M	-$7.691M
YoY Change	25.68%	56.91%	123.32%
Interest Expense	-$57.00K	-$37.00K	-$54.00K
YoY Change	62.86%	-31.48%	-63.27%
% of Operating Profit
Other Income/Expense, Net	-$94.00K	-$21.00K	$0.00
YoY Change	70.91%		-100.0%
Pretax Income	-$20.52M	-$8.760M	-$7.370M
YoY Change	200.0%	18.86%	-0.54%
Income Tax	-$1.210M	-$1.380M
% Of Pretax Income
Net Earnings	-$9.753M	-$12.13M	-$7.745M
YoY Change	26.17%	56.57%	116.28%
Net Earnings / Revenue	-356.99%	-900.89%	-526.15%
Basic Earnings Per Share
Diluted Earnings Per Share	-$156.4B	-$59.98B	-$320.9B
COMMON SHARES
Basic Shares Outstanding	17.57M shares	17.61M shares	16.77M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2018 Q2	2018 Q1	2017 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$1.860M	$840.0K	$18.68M
YoY Change	-83.39%	-95.5%	67.53%
Cash & Equivalents	$24.21M	$33.48M	$41.71M
Short-Term Investments	$1.000M	$0.00	$25.00M
Other Short-Term Assets	$857.0K	$1.187M	$1.004M
YoY Change	21.56%	18.23%	15.4%
Inventory	$1.842M	$1.867M	$928.0K
Prepaid Expenses	$734.0K	$1.006M	$805.0K
Receivables	$3.049M	$2.553M	$1.035M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$30.96M	$39.09M	$69.69M
YoY Change	-51.58%	-43.91%	399.55%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.514M	$1.422M	$903.0K
YoY Change	45.02%	57.48%	201.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$80.00K	$230.0K	$680.0K
YoY Change	-89.04%	-66.18%	11.48%
Total Long-Term Assets	$1.514M	$1.422M	$903.0K
YoY Change	45.02%	57.48%	-0.77%
TOTAL ASSETS
Total Short-Term Assets	$30.96M	$39.09M	$69.69M
Total Long-Term Assets	$1.514M	$1.422M	$903.0K
Total Assets	$32.47M	$40.51M	$70.59M
YoY Change	-50.03%	-42.62%	375.03%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.445M	$2.304M	$530.0K
YoY Change	30.18%	334.72%	103.85%
Accrued Expenses	$4.500M	$5.870M	$3.180M
YoY Change	32.35%	84.59%	-8.62%
Deferred Revenue	$302.0K
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$3.965M	$2.961M	$0.00
YoY Change			-100.0%
Total Short-Term Liabilities	$10.40M	$9.110M	$3.631M
YoY Change	115.82%	150.9%	-61.29%
LONG-TERM LIABILITIES
Long-Term Debt	$5.980M	$6.973M	$9.891M
YoY Change	-39.6%	-29.5%	93.18%
Other Long-Term Liabilities	$0.00	$0.00	$50.00K
YoY Change	-100.0%	-100.0%	-96.89%
Total Long-Term Liabilities	$6.024M	$6.973M	$9.891M
YoY Change	-39.4%	-29.5%	46.97%
TOTAL LIABILITIES
Total Short-Term Liabilities	$10.40M	$9.110M	$3.631M
Total Long-Term Liabilities	$6.024M	$6.973M	$9.891M
Total Liabilities	$16.42M	$16.08M	$13.52M
YoY Change	11.27%	18.94%	-16.06%
SHAREHOLDERS EQUITY
Retained Earnings	-$133.3M	-$123.5M	-$84.35M
YoY Change	44.73%	46.41%
Common Stock	$149.3M	$147.9M	$141.4M
YoY Change	4.9%	4.58%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$16.05M	$24.42M	$57.07M
YoY Change
Total Liabilities & Shareholders Equity	$32.47M	$40.51M	$70.59M
YoY Change	-50.03%	-42.62%	375.03%

Cashflow Statement

Concept	2018 Q2	2018 Q1	2017 Q1
OPERATING ACTIVITIES
Net Income	-$9.753M	-$12.13M	-$7.745M
YoY Change	26.17%	56.57%	116.28%
Depreciation, Depletion And Amortization	$1.390M	$100.0K	$30.00K
YoY Change	3375.0%	233.33%	-25.0%
Cash From Operating Activities	-$6.500M	-$10.60M	-$8.353M
YoY Change	15.04%	26.92%	67.66%
INVESTING ACTIVITIES
Capital Expenditures	-$10.00K	$358.0K	$381.0K
YoY Change	0.0%	-6.04%	746.67%
Acquisitions
YoY Change
Other Investing Activities	-$990.0K	$0.00	-$22.53M
YoY Change	-46.49%	-100.0%	-694.46%
Cash From Investing Activities	-$10.00K	$22.94M	-$22.91M
YoY Change	-99.46%	-200.15%	-711.42%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$0.00
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	7.530M	$28.00K	$0.00
YoY Change	37550.0%		-100.0%
NET CHANGE
Cash From Operating Activities	-6.500M	-$10.60M	-$8.353M
Cash From Investing Activities	-10.00K	$22.94M	-$22.91M
Cash From Financing Activities	7.530M	$28.00K	$0.00
Net Change In Cash	1.020M	$12.37M	-$31.26M
YoY Change	-113.64%	-139.57%	2435.52%
FREE CASH FLOW
Cash From Operating Activities	-$6.500M	-$10.60M	-$8.353M
Capital Expenditures	-$10.00K	$358.0K	$381.0K
Free Cash Flow	-$6.490M	-$10.96M	-$8.734M
YoY Change	15.07%	25.49%	73.74%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2018Q1	dei	Amendment Flag AmendmentFlag	false
CY2018Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2018Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2018Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2018
CY2018Q1	dei	Document Period End Date DocumentPeriodEndDate	2018-03-31
CY2018Q1	dei	Document Type DocumentType	10-Q
CY2018Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001427570
CY2018Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	17572513	shares
CY2018Q1	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2018Q1	dei	Entity Registrant Name EntityRegistrantName	OBALON THERAPEUTICS INC
CY2018Q1	dei	Trading Symbol TradingSymbol	OBLN
CY2017Q4	obln	Accrued Customer Incentives Current AccruedCustomerIncentivesCurrent	558000	USD
CY2018Q1	obln	Accrued Customer Incentives Current AccruedCustomerIncentivesCurrent	556000	USD
CY2017Q4	obln	Accrued Legal And Professional Fees Current AccruedLegalAndProfessionalFeesCurrent	289000	USD
CY2018Q1	obln	Accrued Legal And Professional Fees Current AccruedLegalAndProfessionalFeesCurrent	237000	USD
CY2018Q1	obln	Revenue Recognition Sales Returns Reserve RevenueRecognitionSalesReturnsReserve	200000	USD
CY2017Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1276000	USD
CY2018Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	2304000	USD
CY2017Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	4223000	USD
CY2018Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	2553000	USD
CY2017Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-3000	USD
CY2018Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	5000	USD
CY2017Q4	us-gaap	Accrued Marketing Costs Current AccruedMarketingCostsCurrent	60000	USD
CY2018Q1	us-gaap	Accrued Marketing Costs Current AccruedMarketingCostsCurrent	94000	USD
CY2017Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1415000	USD
CY2018Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1527000	USD
CY2017Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-5000	USD
CY2018Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	1000	USD
CY2017Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	146474000	USD
CY2018Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	147905000	USD
CY2017Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	239000	USD
CY2018Q1	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	621000	USD
CY2017Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	10000	USD
CY2018Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	11000	USD
CY2017Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	914575	shares
CY2018Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1104319	shares
CY2017Q4	us-gaap	Assets Assets	53101000	USD
CY2018Q1	us-gaap	Assets Assets	40507000	USD
CY2017Q4	us-gaap	Assets Current AssetsCurrent	51755000	USD
CY2018Q1	us-gaap	Assets Current AssetsCurrent	39085000	USD
CY2017Q4	us-gaap	Assets Fair Value Disclosure Recurring AssetsFairValueDisclosureRecurring	44400000	USD
CY2018Q1	us-gaap	Assets Fair Value Disclosure Recurring AssetsFairValueDisclosureRecurring	33478000	USD
CY2017Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	USD
CY2018Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	USD
CY2017Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	3000	USD
CY2018Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	0	USD
CY2017Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	23295000	USD
CY2018Q1	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	0	USD
CY2017Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	23292000	USD
CY2018Q1	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	0	USD
CY2017Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	129000	USD
CY2018Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	46000	USD
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	72975000	USD
CY2017Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	41712000	USD
CY2017Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	21108000	USD
CY2018Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	33478000	USD
CY2017Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-31263000	USD
CY2018Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	12370000	USD
CY2018Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	6.1918
CY2018Q1	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	24224	shares
CY2018Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	129000	USD
CY2018Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	100000	USD
CY2017Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.47
CY2017Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2018Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2018Q1	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	5144740	shares
CY2017Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2018Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2017Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2018Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2017Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	17500604	shares
CY2018Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	17596282	shares
CY2017Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	17500604	shares
CY2018Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	17596282	shares
CY2017Q4	us-gaap	Common Stock Value CommonStockValue	18000	USD
CY2018Q1	us-gaap	Common Stock Value CommonStockValue	18000	USD
CY2017Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-7763000	USD
CY2018Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-12120000	USD
CY2017Q1	us-gaap	Cost Of Revenue CostOfRevenue	823000	USD
CY2018Q1	us-gaap	Cost Of Revenue CostOfRevenue	769000	USD
CY2018Q1	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	10000000	USD
CY2018Q1	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	66000	USD
CY2017Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	13000	USD
CY2018Q1	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	0	USD
CY2017Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	510000	USD
CY2018Q1	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	337000	USD
CY2017Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	66000	USD
CY2018Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.71
CY2017Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	4494000	USD
CY2018Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1831000	USD
CY2018Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	9500000	USD
CY2018Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y6M6D
CY2017Q1	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	0	USD
CY2018Q1	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-107000	USD
CY2017Q1	us-gaap	Gross Profit GrossProfit	649000	USD
CY2018Q1	us-gaap	Gross Profit GrossProfit	577000	USD
CY2017Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	217000	USD
CY2018Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1074000	USD
CY2017Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1035000	USD
CY2018Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-1670000	USD
CY2017Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	50000	USD
CY2018Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-173000	USD
CY2017Q1	us-gaap	Increase Decrease In Due From Related Parties Current IncreaseDecreaseInDueFromRelatedPartiesCurrent	-515000	USD
CY2018Q1	us-gaap	Increase Decrease In Due From Related Parties Current IncreaseDecreaseInDueFromRelatedPartiesCurrent	0	USD
CY2017Q1	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-942000	USD
CY2018Q1	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-2663000	USD
CY2017Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	101000	USD
CY2018Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	449000	USD
CY2017Q1	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-240000	USD
CY2018Q1	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-527000	USD
CY2017Q1	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	-94000	USD
CY2018Q1	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	-93000	USD
CY2017Q1	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-54000	USD
CY2018Q1	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-37000	USD
CY2017Q1	us-gaap	Interest Paid InterestPaid	130000	USD
CY2018Q1	us-gaap	Interest Paid InterestPaid	149000	USD
CY2017Q4	us-gaap	Interest Receivable Current InterestReceivableCurrent	85000	USD
CY2018Q1	us-gaap	Interest Receivable Current InterestReceivableCurrent	17000	USD
CY2017Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	245000	USD
CY2018Q1	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	596000	USD
CY2017Q4	us-gaap	Inventory Net InventoryNet	1418000	USD
CY2018Q1	us-gaap	Inventory Net InventoryNet	1867000	USD
CY2017Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	1046000	USD
CY2018Q1	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	1053000	USD
CY2017Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	127000	USD
CY2018Q1	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	218000	USD
CY2017Q4	us-gaap	Liabilities Liabilities	17988000	USD
CY2018Q1	us-gaap	Liabilities Liabilities	16083000	USD
CY2017Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	53101000	USD
CY2018Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	40507000	USD
CY2017Q4	us-gaap	Liabilities Current LiabilitiesCurrent	10011000	USD
CY2018Q1	us-gaap	Liabilities Current LiabilitiesCurrent	9110000	USD
CY2017Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	7977000	USD
CY2018Q1	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	6973000	USD
CY2018Q1	us-gaap	Long Term Debt LongTermDebt	9934000	USD
CY2017Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	1958000	USD
CY2018Q1	us-gaap	Long Term Debt Current LongTermDebtCurrent	2961000	USD
CY2017Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	7964000	USD
CY2018Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	6973000	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	0	USD
CY2018Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	28000	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-22910000	USD
CY2018Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	22944000	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-8353000	USD
CY2018Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-10602000	USD
CY2017Q1	us-gaap	Net Income Loss NetIncomeLoss	-7745000	USD
CY2018Q1	us-gaap	Net Income Loss NetIncomeLoss	-12126000	USD
CY2018Q1	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2017Q1	us-gaap	Operating Expenses OperatingExpenses	8340000	USD
CY2018Q1	us-gaap	Operating Expenses OperatingExpenses	12645000	USD
CY2017Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-7691000	USD
CY2018Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-12068000	USD
CY2018Q1	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	399000	USD
CY2018Q1	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	100000	USD
CY2018Q1	us-gaap	Operating Leases Future Minimum Payments Remainder Of Fiscal Year OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear	299000	USD
CY2017Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	699000	USD
CY2018Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	729000	USD
CY2017Q4	us-gaap	Other Assets Current OtherAssetsCurrent	1714000	USD
CY2018Q1	us-gaap	Other Assets Current OtherAssetsCurrent	1187000	USD
CY2017Q4	us-gaap	Other Assets Miscellaneous Current OtherAssetsMiscellaneousCurrent	115000	USD
CY2018Q1	us-gaap	Other Assets Miscellaneous Current OtherAssetsMiscellaneousCurrent	164000	USD
CY2017Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-18000	USD
CY2018Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	6000	USD
CY2017Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1773000	USD
CY2018Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1677000	USD
CY2017Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	0	USD
CY2018Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-21000	USD
CY2017Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	381000	USD
CY2018Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	358000	USD
CY2017Q1	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	25029000	USD
CY2018Q1	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	0	USD
CY2017Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	1514000	USD
CY2018Q1	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	1006000	USD
CY2017Q1	us-gaap	Proceeds From Maturities Prepayments And Calls Of Shortterm Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments	2500000	USD
CY2018Q1	us-gaap	Proceeds From Maturities Prepayments And Calls Of Shortterm Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments	23302000	USD
CY2017Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	USD
CY2018Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	28000	USD
CY2017Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	2761000	USD
CY2018Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	2949000	USD
CY2017Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1346000	USD
CY2018Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1422000	USD
CY2017Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2400000	USD
CY2018Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2639000	USD
CY2017Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-111374000	USD
CY2018Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-123500000	USD
CY2018Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-123500000	USD
CY2017Q1	us-gaap	Revenues Revenues	1500000	USD
CY2018Q1	us-gaap	Revenues Revenues	1300000	USD
CY2017Q4	us-gaap	Sales And Excise Tax Payable Current SalesAndExciseTaxPayableCurrent	167000	USD
CY2018Q1	us-gaap	Sales And Excise Tax Payable Current SalesAndExciseTaxPayableCurrent	61000	USD
CY2017Q1	us-gaap	Sales Revenue Services Net SalesRevenueServicesNet	1472000	USD
CY2018Q1	us-gaap	Sales Revenue Services Net SalesRevenueServicesNet	1346000	USD
CY2017Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	5940000	USD
CY2018Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	10006000	USD
CY2017Q1	us-gaap	Share Based Compensation ShareBasedCompensation	463000	USD
CY2018Q1	us-gaap	Share Based Compensation ShareBasedCompensation	1389000	USD
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod	50000	shares
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue	10.08
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	125000	shares
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	7.15
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	413000	shares
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	488000	shares
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	9.98
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	9.26
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	0	shares
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue	0.00
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	145369	shares
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	800532	shares
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	1778000	USD
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2979285	shares
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3613770	shares
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	6.49
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	6.64
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	1235000	USD
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	1196515	shares
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	4.70
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	1730000	USD
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	3272697	shares
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	6.54
CY2018Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	1.35
CY2018Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	6.48
CY2018Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	7.02
CY2018Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y10M12D
CY2018Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P6Y6M
CY2018Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P8Y
CY2017Q4	us-gaap	Short Term Investments ShortTermInvestments	23292000	USD
CY2018Q1	us-gaap	Short Term Investments ShortTermInvestments	0	USD
CY2018Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	20678	shares
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	35113000	USD
CY2018Q1	us-gaap	Stockholders Equity StockholdersEquity	24424000	USD
CY2017Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	16562030	shares
CY2018Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	16986656	shares
CY2018Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Concentrations of Credit Risk </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash equivalents and trade accounts receivable, which are generally not collateralized. The Company limits its exposure to credit loss by placing its cash equivalents with high credit quality financial institutions and investing in high quality short-term debt instruments. The Company’s customers consist of physicians and institutions in the United States and one international distributor. The Company establishes customer credit policies related to its accounts receivable based on historical collection experiences within the various markets in which the Company operates, historical past-due amounts, and any specific information that the Company becomes aware of such as bankruptcy or liquidity issues of customers. </font></div></div>
CY2018Q1	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Reclassifications</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">C</font><font style="font-family:inherit;font-size:10pt;">ertain immaterial reclassifications have been made to the prior years’ consolidated financial statements to conform to the current year presentation. These reclassifications have not changed the results of operations.</font></div></div>
CY2018Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Reported amounts and note disclosures reflect the overall economic conditions that are most likely to occur and anticipated measures management intends to take. Actual results could differ materially from those estimates. All revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected.</font></div></div>

Files In Submission

Name	View Source	Status
0001427570-18-000031-index-headers.html	Edgar Link	pending
0001427570-18-000031-index.html	Edgar Link	pending
0001427570-18-000031.txt	Edgar Link	pending
0001427570-18-000031-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
obln-20180331.xml	Edgar Link	completed
obln-20180331.xsd	Edgar Link	pending
obln-20180331_cal.xml	Edgar Link	unprocessable
obln-20180331_def.xml	Edgar Link	unprocessable
obln-20180331_lab.xml	Edgar Link	unprocessable
obln-20180331_pre.xml	Edgar Link	unprocessable
obln-33118x10q.htm	Edgar Link	pending
obln101-33118.htm	Edgar Link	pending
obln311-33118.htm	Edgar Link	pending
obln312-33118.htm	Edgar Link	pending
obln321-33118.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$RSLS
ReShape Lifesciences Inc. Stock $rsls

2018 Q2 Form 10-Q Financial Statement

#000142757018000031 Filed on May 10, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RSLS ReShape Lifesciences Inc. Stock $rsls

2018 Q2 Form 10-Q Financial Statement

#000142757018000031 Filed on May 10, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RSLS
ReShape Lifesciences Inc. Stock $rsls